Table 2.
Treatment effect on target lesions
| DCB-TACE
n=104 |
cTACE
n=86 |
P-value | |
|---|---|---|---|
| Treatment effect, n (%) | |||
| TE4 | 53 (51.0) | 64 (74.4) | |
| TE3 | 14 (13.5) | 11 (12.8) | |
| TE2 | 33 (31.7) | 9 (10.5) | |
| TE1 | 4 (3.8) | 2 (2.3) | |
| Complete response, n (%) | |||
| TE4 | 53 (51.0) | 64 (74.4) | <0.001 |
| TE1/2/3 | 51 (49.0) | 22 (25.6) | |
| Objective response, n (%) | |||
| TE3/4 | 67 (64.4) | 75 (87.2) | <0.001 |
| TE1/2 | 37 (35.6) | 11 (12.8) |
Note. RECICL (Response Evaluation Criteria in Cancer of the Liver) assessment of direct treatment effect on target lesions; TE4; tumor necrosis of 100% or 100% reduction in tumor size, TE3; tumor necrosis of 50-100% or 50-100% reduction in tumor size, TE2; effect other than TE3 or TE1, TE1; tumor enlargement of ≧50% (excluding the area of necrosis after treatment).